- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02950831
Objective Assessment of Activity and Sleep Quality In Burst Spinal Cord Stimulation (OASIS)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Antwerp
-
Wilrijk, Antwerp, Belgium, 2610
- AZ Sint-Augustinus
-
-
Flanders
-
Antwerpen, Flanders, Belgium, 2020
- AZ Middelheim
-
-
-
-
South Holland
-
Rotterdam, South Holland, Netherlands, 3015 CE
- Erasmus MC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is able to provide informed consent to participate in the study;
- Subject is 18 years of age or older;
- Subject has failed to respond to at least 6 months of conventional treatment including pharmacological treatment, physical therapy, epidural injections and/or radiofrequency therapy;
- Subjects with the diagnosis of failed back surgery syndrome or chronic intractable trunk and/or lower limb pain and are eligible for a SCS trial;
- Subjects have an average trunk pain VAS score of at least 6.0 out of 10.0, and/or lower limb pain VAS score of at least 6.0 out of 10.0;
- Subject is on stable pain medications, as determined by the Investigator, for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device;
- Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
- Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
- Subject agrees to wear the wearable sensor for the duration of the study;
- Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study
Exclusion Criteria:
- Subject is currently participating in a clinical investigation that includes an active treatment arm;
- Subject has been implanted with or participated in a trial period for a neurostimulation system;
- Non- ambulatory subjects who are not expected to become ambulatory after receiving neurostimulation;
- Subject diagnosed with fibromyalgia or chronic fatigue;
- Subject has an infusion pump;
- Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
- Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus;
- Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
- Subject is immunocompromised;
- Subjects with concurrent clinically significant or disabling chronic pain problem that requires additional treatment;
- Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
- Subject has history of cancer requiring active treatment in the last 12 months;
- Subject has an existing medical condition that is likely to require the use of diathermy in the future;
- Subject has documented history of allergic response to titanium or silicone;
- Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
- Female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Activity and sleep quality recording
Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
|
Record of activity levels using a wrist worn accelerometer
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Activity Levels
Time Frame: between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Recording performed with wrist worn accelerometer.
Medium to Vigorous Physical Activity (MVPA) were calculated based on accelerometry data.
MVPA value represents the hours of medium to vigorous physical activity in a day.
|
between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Change in Sleep Quality
Time Frame: between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Recording performed with wrist worn accelerometer.
Sleep duration was calculated based on accelerometry data.
|
between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Visual Analog Scale (VAS) for Pain
Time Frame: between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Subjective evaluation of pain levels used in clinical practice as standard.
Minimum value is 0 (no pain), maximum value is 10 (maximum pain imaginable)
|
between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Change in Visual Analog Scale (VAS) for Pain
Time Frame: between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Subjective evaluation of pain levels used in clinical practice as standard.
Minimum value is 0 (no pain), maximum value is 10 (maximum pain imaginable)
|
between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Change in Visual Analog Scale (VAS) for Pain
Time Frame: between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Subjective evaluation of pain levels used in clinical practice as standard.
Minimum value is 0 (no pain), maximum value is 10 (maximum pain imaginable)
|
between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Change in Visual Analog Scale (VAS) for Pain
Time Frame: between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Subjective evaluation of pain levels used in clinical practice as standard.
Minimum value is 0 (no pain), maximum value is 10 (maximum pain imaginable)
|
between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Change in European Quality of Life 5 Dimensions (EQ-5D)
Time Frame: between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Questionnaire pertaining to quality of life.
Minimum Value 0, maximum value 1 with higher numbers representing higher quality of life.
|
between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Change in European Quality of Life 5 Dimensions (EQ-5D)
Time Frame: between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Questionnaire pertaining to quality of life.
Minimum Value 0, maximum value 1 with higher numbers representing higher quality of life
|
between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Change in European Quality of Life 5 Dimensions (EQ-5D)
Time Frame: between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Questionnaire pertaining to quality of life.
Minimum Value 0, maximum value 1 with higher numbers representing higher quality of life
|
between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Change in European Quality of Life 5 Dimensions (EQ-5D)
Time Frame: between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Questionnaire pertaining to quality of life.
Minimum Value 0, maximum value 1 with higher numbers representing higher quality of life
|
between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Change in Oswestry Disability Index (ODI)
Time Frame: between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Questionnaire pertaining to disability levels.
Minimum value 0, maximum value 100 with higher values representing higher levels of disability.
|
between baseline and the end of spinal cord stimulation trial period (average of 1 month)
|
Change in Oswestry Disability Index (ODI)
Time Frame: between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Questionnaire pertaining to disability levels.
Minimum value 0, maximum value 100 with higher values representing higher levels of disability.
|
between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Change in Oswestry Disability Index (ODI)
Time Frame: between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Questionnaire pertaining to disability levels.
Minimum value 0, maximum value 100 with higher values representing higher levels of disability.
|
between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Change in Oswestry Disability Index (ODI)
Time Frame: between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Questionnaire pertaining to disability levels.
Minimum value 0, maximum value 100 with higher values representing higher levels of disability.
|
between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Change in Activity Levels
Time Frame: between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Recording performed with wrist worn accelerometer. Medium to Vigorous Physical Activity (MVPA) were calculated based on accelerometry data. MVPA value represents the hours of medium to vigorous physical activity in a day. Average percent change in MVPA from baseline value is reported. |
between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Change in Sleep Quality
Time Frame: between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Recording performed with wrist worn accelerometer.
Sleep duration was calculated based on accelerometry data.
|
between baseline and 1 month post permanent spinal cord stimulator activation followup
|
Change in Activity Levels
Time Frame: between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Recording performed with wrist worn accelerometer. Medium to Vigorous Physical Activity (MVPA) were calculated based on accelerometry data. MVPA value represents the hours of medium to vigorous physical activity in a day. Average percent change in MVPA from baseline value is reported. |
between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Change in Sleep Quality
Time Frame: between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Recording performed with wrist worn accelerometer.
Sleep duration was calculated based on accelerometry data.
|
between baseline and 2 month post permanent spinal cord stimulator activation followup
|
Change in Activity Levels
Time Frame: between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Recording performed with wrist worn accelerometer. Medium to Vigorous Physical Activity (MVPA) were calculated based on accelerometry data. MVPA value represents the hours of medium to vigorous physical activity in a day. Average percent change in MVPA from baseline value is reported. |
between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Change in Sleep Quality
Time Frame: between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Recording performed with wrist worn accelerometer.
Sleep duration was calculated based on accelerometry data.
|
between baseline and 3 month post permanent spinal cord stimulator activation followup
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SJM-CIP-10133
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, Chronic | Video-Assisted Thoracoscopic SurgeryTurkey
Clinical Trials on Accelerometry
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)Completed
-
University of MinnesotaRecruitingPeripheral Artery DiseaseUnited States
-
University of California, San FranciscoCompleted
-
Universidad Pública de NavarraDaiichi Sankyo, Inc.; Sociedad Española De Medicina InternaRecruitingAtrial Fibrillation | Physical Inactivity | Thromboprophylaxis | Thromboembolism, Venous | Hospital at HomeSpain
-
MindRhythm, Inc.Wayne State University; Western Michigan UniversityCompletedCOVID-19 | Stroke, AcuteUnited States
-
SymmetryScience Group, Inc.CompletedHealthy | Eczema | Atopic DermatitisUnited States
-
Hoffmann-La RocheCompletedIdiopathic Pulmonary Fibrosis | Interstitial Lung DiseaseNetherlands, Ireland, France, Italy, Canada, Russian Federation
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHematopoietic Stem Cell TransplantationUnited States
-
Boston UniversityPfizerTerminatedAtopic DermatitisUnited States
-
University GhentCompletedDementia | Gait | Muscle Tone | Balance | Paratonia | Fine Motor FunctionBelgium